deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02296138

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]

Sponsor: Boehringer Ingelheim

Updated 14 times since 2017 Last updated: May 31, 2018 Started: Jan 13, 2015 Primary completion: Mar 8, 2017 Completion: Mar 29, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 14 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2021 · 30 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

14 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Dec 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Nov 2025 — Dec 2025 [monthly]

    Completed PHASE3

  4. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  5. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

Show 9 earlier versions
  1. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  2. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

  4. Jul 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE3

  6. Jan 2018 — Jun 2018 [monthly]

    Completed PHASE3

  7. Sep 2017 — Jan 2018 [monthly]

    Completed PHASE3

  8. Jun 2017 — Sep 2017 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  9. Jan 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .